School of Engineering and Built Environment, Griffith University, Engineering Drive, Southport, QLD 4222, Australia; Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran; Queensland Micro- and Nanotechnology Centre, Griffith University, West Creek Road, Nathan QLD 4111, Australia.
Department of Animal Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Acta Biomater. 2021 May;126:238-248. doi: 10.1016/j.actbio.2021.03.036. Epub 2021 Mar 23.
The stem cell-based retinal ganglion cells (RGCs) replacement therapy offers a potential to restore vision in progressive optic neuropathies including glaucoma by replacing degenerated RGCs and by simulating axonal regeneration. Injured optic nerve axons do not regenerate owing to the limited intrinsic capacity of the neurons and the inhibitory environment at the injury site. Polymeric tissue scaffolds are able to modulate the physical environment while providing structural support for transplanted cells, however, their application specific to the RGC generation has been far from conclusive. The successful generation of clinically safe and functional RGCs that can appropriately integrate into the hosts' retinas still remain largely unresolved. Our study reports on a process that enables generation of RGCs from human embryonic stem cells (hESCs) that is simple, straightforward and repeatable and, investigates the influence of the aligned poly(glycerol sebacate) (PGS)/poly(ε-caprolactone) (PCL) scaffold on this differentiation process. Our findings demonstrate that PGS/PCL scaffold promotes differentiation of hESCs into RGC-like cells possibly by the simulation of cell active environmental signalling and, facilitates the growth of RGCs neurites along their lengths. STATEMENT OF SIGNIFICANCE: Glaucoma can lead to the degeneration of retinal ganglion cells (RGCs), with consequential vision loss. RGCs are incapable of self-renewal, replacement of diseased RGCs with healthy cells has been a goal to restore vision in glaucoma patients. In this regard, stem cell RGC replacement therapy has been shown to improve vision in animal models of glaucoma, which could be facilitated by using tissue-engineered polymeric scaffolds. In this study, we generated homogenous stem cell-derived RGCs via a straightforward differentiation protocol and evaluated the effects of PGS/PCL scaffold on RGCs differentiation and growth of RGCs neurites. Our study contributes to the knowledge on how biomaterial scaffolds are able to support the regeneration of RGC neurites (i.e., axons or dendrites) as a part of a possible future clinical therapy for the treatment of glaucoma.
基于干细胞的视网膜神经节细胞 (RGC) 替代疗法为包括青光眼在内的进行性视神经病变提供了一种通过替代变性 RGC 并模拟轴突再生来恢复视力的潜力。受伤的视神经轴突不会再生,这是由于神经元的内在能力有限和损伤部位的抑制环境。聚合物组织支架能够调节物理环境,同时为移植细胞提供结构支撑,然而,它们在 RGC 生成方面的应用还远未得出结论。从人类胚胎干细胞 (hESC) 生成能够适当整合到宿主视网膜中的临床安全且功能齐全的 RGC 仍然存在很大的问题。我们的研究报告了一种从 hESC 生成 RGC 的简单、直接且可重复的过程,并研究了对齐的聚 (甘油癸二酸酯) (PGS)/聚 (ε-己内酯) (PCL) 支架对这一分化过程的影响。我们的研究结果表明,PGS/PCL 支架通过模拟细胞活跃的环境信号促进 hESC 分化为 RGC 样细胞,并促进 RGC 轴突沿着其长度生长。
青光眼可导致视网膜神经节细胞 (RGC) 变性,导致视力丧失。RGC 不能自我更新,用健康细胞替代患病的 RGC 一直是恢复青光眼患者视力的目标。在这方面,干细胞 RGC 替代疗法已被证明可改善青光眼动物模型的视力,使用组织工程聚合物支架可促进其改善。在这项研究中,我们通过一种简单的分化方案生成了同质的干细胞衍生的 RGC,并评估了 PGS/PCL 支架对 RGC 分化和 RGC 轴突生长的影响。我们的研究有助于了解生物材料支架如何能够支持 RGC 轴突(即轴突或树突)的再生,作为治疗青光眼的未来临床治疗的一部分。